Atherosclerotic occlusive disease of the renal arteries in elderly patients, when associated with hypertension and progressive renal insufficiency is termed 'ischaemic nephropathy'. Bilateral atherosclerotic occlusive disease is now recognised as a frequent cause of end-stage renal disease (ESRD) and is often amenable to therapy.
Studies assessing patients with ESRD, being evaluated for dialysis, have suggested that atherosclerotic renal artery disease was a likely cause or primary contributor to ESRD in 6% of the population studied. For patients over the age of 50 years, the prevalence increased to 14%. There are now several studies suggesting that 14 -16% of patients coming to dialysis with ESRD have bilateral total occlusion of the renal arteries. This is a reversible cause of ESRD in selected patients. Unilateral or bilateral revascularisation, performed selectively, has facilitated removal from dialysis for some patients. Early experience in this patient population was with surgical revascularisation, but over the last decade the use of transluminal angioplasty with stent placement has effectively revascularised occluded kidneys.
It has also been observed that the prevalence of secondary hypertension increases significantly in hypertensive individuals over age 60 years. In this population the most common causes of secondary hypertension are renal artery stenosis, due to atherosclerotic occlusive disease, or thyroid disease, particularly hypothyroidism. Numerous studies in patients with generalised atherosclerotic disease have also documented increased prevalence of atherosclerotic renal artery stenosis. In patients who present with peripheral vascular disease, severe aortic atherosclerosis, aortic abdominal aneurysm, and coronary artery disease with hypertension, the prevalence of associated renal artery stenosis ranges from 16 to 40%.
The recognition of selected clinical clues to the presence of ischaemic renal disease can facilitate the diagnosis. Consider screening patients for renal artery stenosis when the following clinical clues are present:
• new onset of hypertension after age 55 years;
• episodes of flash pulmonary oedema in the setting of poorly controlled hypertension and azotemia; • acute renal failure following initiation of angiotensin-converting enzyme inhibitors (ACEi); • azotemia in the elderly patient with peripheral vascular disease, aortic, or coronary disease; • azotemia associated with the recent onset of difficult-to-control hypertension; • progressive azotemia with known renovascular hypertension; • azotemia in the presence of abdominal or flank bruits; • undiagnosed renal failure, especially in the presence of a bland urinary sediment.
Keep in mind that longstanding nephrosclerosis and/or atheroembolism may complicate the course of ischaemic nephropathy. Similar clinical clues may be observed in patients with longstanding arteriolar nephrosclerosis with essential hypertension. Patients with severe aortic atherosclerotic plaque disease are increasingly prone to spontaneous episodes of atheroemboli. 1 It is common to see all three of these entities in the same patient at the time of evaluation. Advances in renal artery revascularisation, especially percutaneous transluminal angioplasty and renal artery stenting have stimulated the development of improved, noninvasive screening modalities to identify patients with potentially correctable renovascular disease. While angiography, with or without digital subtraction, remains the gold standard for the diagnosis of renovascular disease, it is, nevertheless, an interventional procedure in patients with generalised atherosclerosis. Cannulation of the abdominal aorta carries small, but significant risks of bleeding, atheroembolism, and contrast nephrotoxicity. We prefer to delay invasive angiography until such time that a revascularisation is planned. Several noninvasive screening tests have emerged as very useful in identifying patients with renal artery occlusive disease. The most useful screening tests would appear to be captopril renography, duplex ultrasound scanning of the renal arteries, and magnetic resonance (MR) angiography.
Duplex ultrasound scanning
Our preferred noninvasive screening test for the presence of renal artery stenosis is duplex ultrasound scanning. 2 This technique involves using a combination of direct visualisation of the renal artery with B-mode imaging and then measurement of the velocity of blood flow, using a pulse-wave doppler. A ratio of peak systolic velocity in the renal artery to peak systolic velocity in the aorta enables an estimate of the degree of arterial stenosis present. We have found a very high sensitivity and specificity for this technique when compared with the gold standard, contrast angiography. Duplex ultrasound scanning is noninvasive, requires no contrast material, and is more cost effective than contrast angiography or MR angiography. The technique is very operator-dependent and can require considerable time, especially in obese patients. Because of these human factors, results may vary widely and have limited the use of this screening tool in many centers. Duplex ultrasound is also a very useful procedure following intervention and enables periodic long-term follow-up of vessel patency.
Magnetic resonance (MR) angiography
When used with gadolinium, a non-toxic intravenous contrast agent, MR angiography provides enhanced images of the proximal renal vasculature. Preliminary studies have suggested sensitivity rates of 85 to 100% in the detection of main renal artery stenosis. Unfortunately, MR angiography is less sensitive in detecting branch or accessory renal artery stenosis, and it may overestimate the degree of stenosis in areas of turbulent flow. MR angiography has become a popular screening tool in centres
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Captopril renography
By combining the use of an ACEi with radioactive renography, the sensitivity and specificity of this procedure were markedly increased. In a patient with haemodynamically significant stenosis, captopril may produce an acute and readily reversible decrease in renal function on the side of the renal artery stenosis. Sensitivity and specificity with this procedure are high, in the range of 93 to 95% respectively, in patients with renal artery stenosis and normal renal function. Unfortunately, the sensitivity decreases in the presence of bilateral renal artery stenosis or in patients with significant azotemia. Regrettably this is a patient population that benefits most from a good, noninvasive screening test.
Renal angiography
Conventional angiography remains the standard for definitive diagnosis, even though it requires larger volumes of contrast medium and carries attendant risks of atheroembolism and contrast-induced renal tubular necrosis. It does provide superior images of the renal arteries and peripheral branches and allows critical viewing of the aorta and collateral circulation to determine whether revascularisation is feasible.
Intra-arterial digital subtraction angiography (IADSA) provides images that can be comparable to conventional angiography. A smaller volume of contrast is required, and smaller size catheters may be used for injection which may reduce the risk of intra-aortic damage, thus, reducing the risk of atheroembolization. CO 2 angiography combined with IADSA may provide high quality images with a lower volume of contrast, but is technically more difficult to perform. It can markedly reduce the amount of contrast required for the angiographic procedure.
Assessing the patient: risks and options
In the elderly patient with an increased prevalence of generalised atherosclerotic disease, complex medical problems, and variable hypertension, management represents a significant challenge. Increasingly, revascularisation procedures are focused on preservation of renal function since blood pressure in most patients can be controlled with currently available antihypertensive agents. A comparison of treatment procedures is difficult because most analyses have been uncontrolled, selection criteria vary greatly, and many are retrospective. Earlier reviews suggested that surgery appeared more effective than PTRA in preserving kidney function while procedural mortality and morbidity rates were simi-
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Journal of Human Hypertension lar. 3 More recent studies suggest that PTRA can be a very effective treatment for both hypertension and preservation of renal function. 4 Factors in determining the success of PTRA, like surgical intervention, include the location of the lesion (osteal vs nonosteal), and pre-procedural renal function. With PTRA, early restenosis has been a major factor limiting the clinical success of this intervention. A recent prospective, randomised study of PTRA vs surgical revascularisation as initial therapy showed no differences with regard to technical results, primary and secondary patency, or effects on renal function in patients with atherosclerotic unilateral renal artery stenosis. PTRA was recommended as initial therapy if combined with intensive follow-up and aggressive re-intervention. 5 Renal artery stenting has become an important adjunct to PTRA, being used to counteract the elastic recoil and abolish the residual stenosis often observed after PTRA. Stenting following PTRA of osteal lesions has been associated with improved patency at 6 and 12 months. Stent placement provides the immediate advantage of preventing recoil, but does not prevent restenosis. Like PTRA, the potential advantages of stents must be balanced with the risks of the procedure.
A decision to proceed with an intervention should hinge on careful assessment of the risks vs benefits of the revascularisation procedure, 6 the risks of developing progressive renal failure, together with the age and associated clinical conditions present. Keep in mind that many patients with vascular disease may have asymptomatic atherosclerotic renal artery stenosis with normal or near normal blood pressure and renal function. These patients should not be exposed to the complications of renal artery revascularisation. Patients with atherosclerotic renal artery stenosis and mild renal insufficiency have a higher likelihood of dying from a stroke or myocardial infarction than the risk of progressing to ESRD. However, patients with renal artery stenosis and moderate-to-severe renal failure carry a higher risk for both ESRD and cardiovascular death. These patients are therefore candidates for revascularisation. Unfortunately, retrospective studies also suggest that they may be at higher risk for procedural complications.
The impact of new antihypertensive agents on the management of renovascular hypertension has also been remarkable. Because of improved blood pressure control, many patients with renovascular hypertension are not identified. A critical question then is to balance the risks of progressive renal artery stenosis and progressive renal failure against the risk of a revascularisation procedure.
Several clinical studies have compared PTRA with antihypertensive medication to medication alone. Overall, differences in final blood pressure between patients allocated to PTRA and those allocated to medication were minimal, and only a minority of patients undergoing PTRA could discontinue medication therapy. On the other hand, it has been observed that the number of antihypertensive agents required to control blood pressure adequately was lower after PTRA than with medication alone. This would appear to be an advantage of PTRA over conservative treatment in patients with resistant hypertension.
A practical approach to management
Currently, we take a cautious and conservative approach to the elderly patient with generalised atherosclerosis and suspected ischaemic nephropathy. We avoid interventive diagnostic angiographic procedures in these patients, not only because of the increased risk of contrast-induced renal dysfunction, but also because of the risk of atheroembolic events associated with aortic cannulation. 7 We rely on noninvasive duplex ultrasound or MR angiography with gadolinium enhancement which can provide acceptable imaging of the aorta and main renal arteries. By using frequent clinical assessment of renal function together with noninvasive imaging techniques, evidence of disease progression can be monitored, enabling a decision regarding the most appropriate timing of an intervention. Invasive angiography should be avoided if at all possible until such time that an intervention is planned as part of the procedure. The persistence of hypertension resistant to appropriate three-or four-drug therapy also presents an indication for considering an intervention.
In the presence of progressive deterioration of renal function or uncontrolled high blood pressure, the best window of opportunity would appear to be in those patients with creatinine levels between 1.5 and 3 mg/dl. 8 Conversely, patients with normal renal function and well-controlled blood pressure can be expected to gain little from a renal revascularisation. Careful evaluation of coronary and cerebrovascular circulation systems are critical prior to considering a revascularisation procedure. When an intervention is indicated, we have increasingly relied on PTRA with stenting particularly for proximal atherosclerotic lesions. This combined procedure maximises longterm patency, but does not obviate the risk of restenosis. In occasional patients with unilateral renal artery occlusion, an atrophied kidney and uncontrolled hypertension, a laparoscopic nephrectomy can improve the ease of blood pressure control.
Most patients undergoing angioplasty or surgical revascularisation will still require antihypertensive therapy following the procedure. 9 The reduction in the number of drugs required by patients undergoing angioplasty, while a benefit of the procedure, must be weighed against the risks of both restenosis and complications associated with the procedure.
In patients with ischaemic nephropathy, but with stable renal function and controllable hypertension, the benefits of conservative blood pressure control need to be compared to the potential benefits of revascularisation on blood pressure control and renal function. Prospective studies comparing the long-term effects of medical vs surgical therapy on morbidity and mortality are obviously needed.
